PL2641601T3 - Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibu - Google Patents
Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibuInfo
- Publication number
- PL2641601T3 PL2641601T3 PL13168383T PL13168383T PL2641601T3 PL 2641601 T3 PL2641601 T3 PL 2641601T3 PL 13168383 T PL13168383 T PL 13168383T PL 13168383 T PL13168383 T PL 13168383T PL 2641601 T3 PL2641601 T3 PL 2641601T3
- Authority
- PL
- Poland
- Prior art keywords
- huluc63
- bortezomib
- methods
- multiple myeloma
- combination therapies
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title 1
- 229960001467 bortezomib Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 229960004137 elotuzumab Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83618506P | 2006-08-07 | 2006-08-07 | |
| US94426207P | 2007-06-15 | 2007-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2641601T3 true PL2641601T3 (pl) | 2017-01-31 |
Family
ID=38831279
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13168383T PL2641601T3 (pl) | 2006-08-07 | 2007-08-07 | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibu |
| PL07840746T PL2068874T3 (pl) | 2006-08-07 | 2007-08-07 | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07840746T PL2068874T3 (pl) | 2006-08-07 | 2007-08-07 | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8632772B2 (show.php) |
| EP (5) | EP2641600A1 (show.php) |
| JP (1) | JP5340935B2 (show.php) |
| CN (1) | CN101686971B (show.php) |
| AU (1) | AU2007281684C1 (show.php) |
| BR (1) | BRPI0716647A2 (show.php) |
| CA (1) | CA2660356C (show.php) |
| CY (5) | CY1116247T1 (show.php) |
| DK (2) | DK2641601T3 (show.php) |
| ES (2) | ES2589302T3 (show.php) |
| HR (2) | HRP20150449T1 (show.php) |
| HU (4) | HUE029027T2 (show.php) |
| IL (2) | IL196919A (show.php) |
| LT (4) | LT2641601T (show.php) |
| LU (3) | LU93276I2 (show.php) |
| MX (1) | MX2009001441A (show.php) |
| NL (1) | NL300840I2 (show.php) |
| NO (1) | NO346835B1 (show.php) |
| NZ (1) | NZ574978A (show.php) |
| PL (2) | PL2641601T3 (show.php) |
| PT (2) | PT2641601T (show.php) |
| SI (2) | SI2641601T1 (show.php) |
| WO (1) | WO2008019378A1 (show.php) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2641600A1 (en) | 2006-08-07 | 2013-09-25 | AbbVie Biotherapeutics Inc. | Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies |
| DK2068930T3 (da) | 2006-08-07 | 2012-10-29 | Abbott Biotherapeutics Corp | Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer |
| CA2726804C (en) * | 2008-06-02 | 2021-12-28 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| KR20110028450A (ko) | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
| EP3090737A1 (en) * | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| ES2502541T3 (es) | 2009-09-10 | 2014-10-03 | Kyowa Hakko Kirin Co., Ltd. | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) |
| US8841325B2 (en) * | 2009-11-24 | 2014-09-23 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells |
| CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| EP3066128B1 (en) * | 2013-11-06 | 2018-10-31 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| NZ717673A (en) | 2013-11-21 | 2020-02-28 | Hoffmann La Roche | Anti-alpha-synuclein antibodies and methods of use |
| HRP20230265T1 (hr) * | 2014-08-22 | 2023-04-14 | Celgene Corporation | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima |
| US10752902B2 (en) * | 2014-09-23 | 2020-08-25 | Board Of Trustees Of Michigan State University | Compositions comprising fusion proteins useful for modulating an immune response |
| US10365280B2 (en) | 2014-10-02 | 2019-07-30 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| EA201791049A1 (ru) * | 2014-12-04 | 2017-10-31 | Бристол-Майерс Сквибб Компани | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) |
| AU2016260895B2 (en) | 2015-05-13 | 2021-08-05 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| DK3313528T3 (da) * | 2015-06-29 | 2021-09-20 | Bristol Myers Squibb Co | Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer |
| CN105688185B (zh) * | 2016-03-13 | 2019-03-19 | 浙江药苑生物科技有限公司 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
| WO2018182529A1 (en) * | 2017-03-29 | 2018-10-04 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| CN111373246A (zh) * | 2017-11-22 | 2020-07-03 | 希成生物医药 | 包括硼替佐米的聚合物纳米颗粒 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN115298549A (zh) | 2019-11-05 | 2022-11-04 | 百时美施贵宝公司 | M蛋白测定及其用途 |
| CN115368462B (zh) * | 2022-07-19 | 2026-01-02 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| WO1996037208A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| KR100822149B1 (ko) * | 2002-05-17 | 2008-04-15 | 셀진 코포레이션 | 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물 |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| JP2008519028A (ja) * | 2004-11-04 | 2008-06-05 | フィブロン リミテッド | Ｂ細胞悪性腫瘍の治療 |
| EP2641600A1 (en) | 2006-08-07 | 2013-09-25 | AbbVie Biotherapeutics Inc. | Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies |
| DK2068930T3 (da) | 2006-08-07 | 2012-10-29 | Abbott Biotherapeutics Corp | Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer |
| US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
-
2007
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en not_active Ceased
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
-
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
-
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
-
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
-
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I2/el unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
-
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2641601T (lt) | Daugybinės mielomos, naudojant kombinuotas terapijas, pagrįstas huluc63 su bortezomibu, gydymo būdai | |
| IL257418A (en) | Methods for treating addiction | |
| DK3067067T3 (en) | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | |
| IL193920A0 (en) | Methods of treating lupus using cd4 antibodies | |
| ZA200807715B (en) | 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders | |
| EP2114553A4 (en) | SYSTEM AND METHOD FOR INJECTING INHIBITORS | |
| GB2467710B (en) | Methods for treating social disorders | |
| IL213476A0 (en) | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles | |
| EP2170311A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | |
| SI2029155T1 (sl) | Izboljšano zdravljenje multiplega mieloma | |
| IL196920A0 (en) | Compositions and methods using anti-csi antibodies to treat multiple myeloma | |
| IL209360A0 (en) | Multiple myeloma treatments | |
| PL2131841T3 (pl) | Sposoby leczenia bólu ostrego | |
| EP2205271A4 (en) | COMPOSITIONS AND METHODS OF THERAPIES BASED ON RIBONUCLEASE BASE | |
| ZA200807524B (en) | Methods of treating lupus using CD4 antibodies | |
| SI2068930T1 (sl) | Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma | |
| ZA200903242B (en) | Treatment for multiple myeloma | |
| HK1131318A (en) | Methods of using saha and bortezomib for treating multiple myeloma | |
| HK1167807A (en) | Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan | |
| ZA201000867B (en) | Methods for treating dependence | |
| GB0619251D0 (en) | T cell therapies |